Cell death & disease

The lncRNA TP73-AS1 is linked to aggressive glioblastoma and helps cancer stem cells resist chemotherapy

Updated

Abstract

TP73-AS1 is significantly overexpressed in primary glioblastoma samples, particularly in tumor-initiating cells.

  • High expression levels of TP73-AS1 are associated with poor prognosis in glioma and glioblastoma patients.
  • TP73-AS1 may promote resistance to temozolomide in glioblastoma .
  • Downregulation of TP73-AS1 using CRISPRi reduces therapy resistance in glioblastoma cancer stem cells.
  • TP73-AS1 is linked to the regulation of genes related to metabolism and the cancer stem cell marker ALDH1A1.

Simplified

Key numbers

<10%
Survival Rate
5-year overall survival rate for patients
500 µM
Increased Sensitivity to TMZ
Dose of TMZ that led to increased sensitivity in upon TP73-AS1 knockdown

Full Text

What this is

  • () has a low survival rate, with less than 10% of patients surviving five years.
  • () contribute to treatment resistance and recurrence in .
  • This research identifies the () TP73-AS1 as a significant factor in aggressiveness and temozolomide (TMZ) resistance.

Essence

  • High levels of TP73-AS1 in glioblastoma correlate with poor patient outcomes and promote resistance to temozolomide in . This may serve as both a prognostic biomarker and a therapeutic target.

Key takeaways

  • TP73-AS1 is overexpressed in glioblastoma samples, particularly in , indicating its role in tumor aggressiveness.
  • Silencing TP73-AS1 in increases sensitivity to temozolomide, suggesting it protects these cells from chemotherapy.
  • The expression of TP73-AS1 is linked to the regulation of metabolism-related genes, which may contribute to therapy resistance.

Caveats

  • The exact mechanisms by which TP73-AS1 influences TMZ resistance remain unclear and require further investigation.
  • Findings are based on specific models, which may not fully represent all contexts.

Definitions

  • glioblastoma multiforme (GBM): A highly aggressive brain tumor with a poor prognosis and low survival rates.
  • long noncoding RNA (lncRNA): RNA molecules longer than 200 nucleotides that do not encode proteins but can regulate gene expression.
  • cancer stem cells (gCSC): A subset of cells within tumors that drive growth, metastasis, and resistance to therapies.

Simplified

Funding

Competing interests

The authors declare that they have no conflict of interest.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free